For Drug deals,small is beautiful 9227/346

据 wsj mar 8,2009 报导.Big Pharma has shocked the deals market back to life,Health-care companies have annouced $128 billion in deals to date in 2009.
on Thursday,biotech even threw up a rare fight over a target company when Gilead Sciences trumped Astellas Pharma's hostile bid for CV Therapeutics. that deal makes some sense.CV has plenty of growth potential through Ranexa,its leading cardiovascular drug,but is strapped for cash.Pfizer will lose most of the $12 billion in annual revenue from Lipitor when its patent expires. But J&Js largest single drug is Remicade,with $3.7 billion of annual sales and protection until 2018. Abbott's Humira has $4.5 billion in annual sales, and a patent that won't expire until 2017.